We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Elan Targeted In Off-Label Marketing Probe

Law360 (March 5, 2007, 12:00 AM EST) -- Irish pharmaceutical company Elan Corp. is facing a kickback probe from the U.S. Department of Justice and the Department of Health over the promotion of epilepsy drug Zonegran for off-label uses.

Zonegran, also known as zonisamide, is approved in the United States for the treatment of partial epileptic seizures in adults.

The drug was marketed by Elan from 2000 to 2004, when it sold its interests in Zonegran to Eisai Co. Ltd. for approximately $130 million.

Researchers are investigating its use in treating tremors for Parkinson’s...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.